Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R D Carr

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Diabetologia|November 27, 2004
Reduction of beta cell mass: partial insulin secretory compensation from the residual beta cell population in the nicotinamide-streptozotocin Göttingen minipig after oral glucose in vivo and in the perfused pancreasM O Larsen, B Rolin, C F Gotfredsen, et al.
Diabetes, Obesity & Metabolism|June 4, 2011
GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic miceC G Jolivalt, M Fineman, C F Deacon, et al.
Diabetologia|March 11, 2003
Loss of beta-cell mass leads to a reduction of pulse mass with normal periodicity, regularity and entrainment of pulsatile insulin secretion in Göttingen minipigsM O Larsen, C F Gotfredsen, M Wilken, et al.
Diabetes, Obesity & Metabolism|January 22, 2013
Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjectsL Ohlsson, W Alsalim, R D Carr, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1996
Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasmaL Pridal, C F Deacon, O Kirk, et al.
Diabetologia|October 16, 2002
The conscious Göttingen minipig as a model for studying rapid pulsatile insulin secretion in vivoM O Larsen, M Elander, J Sturis, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 7, 2009
Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki ratsL Simonsen, S Pilgaard, R D Carr, et al.
Neuroreport|October 1, 1992
Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-mazeF C Kaiser, G C Palmer, A V Wallace, et al.
Diabetes, Obesity & Metabolism|March 7, 2012
Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203R D Carr, H L Katzeff, C M Alexander, et al.
British Journal of Pharmacology|May 1, 1990
Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the ratR D Carr, A E Cooper, R Hutchinson, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Diabetologia|November 27, 2004
Reduction of beta cell mass: partial insulin secretory compensation from the residual beta cell population in the nicotinamide-streptozotocin Göttingen minipig after oral glucose in vivo and in the perfused pancreasM O Larsen, B Rolin, C F Gotfredsen, et al.
Diabetes, Obesity & Metabolism|June 4, 2011
GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic miceC G Jolivalt, M Fineman, C F Deacon, et al.
Diabetologia|March 11, 2003
Loss of beta-cell mass leads to a reduction of pulse mass with normal periodicity, regularity and entrainment of pulsatile insulin secretion in Göttingen minipigsM O Larsen, C F Gotfredsen, M Wilken, et al.
Diabetes, Obesity & Metabolism|January 22, 2013
Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjectsL Ohlsson, W Alsalim, R D Carr, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1996
Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasmaL Pridal, C F Deacon, O Kirk, et al.
Diabetologia|October 16, 2002
The conscious Göttingen minipig as a model for studying rapid pulsatile insulin secretion in vivoM O Larsen, M Elander, J Sturis, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|July 7, 2009
Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki ratsL Simonsen, S Pilgaard, R D Carr, et al.
Neuroreport|October 1, 1992
Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-mazeF C Kaiser, G C Palmer, A V Wallace, et al.
Diabetes, Obesity & Metabolism|March 7, 2012
Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203R D Carr, H L Katzeff, C M Alexander, et al.
British Journal of Pharmacology|May 1, 1990
Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the ratR D Carr, A E Cooper, R Hutchinson, et al.
Pageof 4